| Literature DB >> 28279423 |
Yong-Hyun Kim1, Jennifer Kirsop2, Wai Hong Wilson Tang3.
Abstract
Chemotherapy-related cardiac dysfunction (CRCD) has challenged clinicians to hesitate in using cardiotoxic agents such as anthracycline and several protein kinase inhibitors. As early detection of CRCD and timely cessation of cardiotoxic agents became a strategy to avoid CRCD, cardiac troponin and natriuretic peptide are measured to monitor cardiotoxicity; however, there are inconsistencies in their predictability of CRCD. Alternative biomarkers have been researched extensively for potential use as more sensitive and accurate biomarkers. The mechanisms of CRCD and previous studies on traditional and novel biomarkers for CRCD are examined to enlighten future direction of investigation in this combined biology.Entities:
Keywords: Biomarkers; Chemotherapy-related cardiac dysfunction; Heart failure; Malignancy
Mesh:
Substances:
Year: 2017 PMID: 28279423 PMCID: PMC5347470 DOI: 10.1016/j.hfc.2016.12.009
Source DB: PubMed Journal: Heart Fail Clin ISSN: 1551-7136 Impact factor: 3.179